Pulse Biosciences Inc Stock Price, News & Analysis

Pulse Biosciences (PLSE) announced preliminary unaudited financial results for Q4 2021, estimating full-year revenue between $1.3 million to $1.4 million and Q4 revenue around $750 thousand. The company completed its first two commercial sales of the CellFX System and transitioned 17 Controlled Launch Program participants to commercial use, totaling 29 conversions. Regulatory approvals were achieved in the U.S., Europe, and Canada, setting the stage for growth in 2022.

Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stephens Annual Investment Conference in Nashville, Tennessee, scheduled for December 2, 2021. Management will engage in a fireside chat at 2:00 PM PT / 4:00 PM CT. Interested individuals can access the live and recorded webcast via the company’s website.

Pulse Biosciences specializes in bioelectric medicine, leveraging its CellFX® System and Nano-Pulse Stimulation™ technology to improve dermatologic outcomes.

Pulse Biosciences, Inc. (Nasdaq: PLSE) announced its third quarter 2021 financial results, reporting revenue of $574,000, with 12 Controlled Launch Program participants opting to acquire CellFX Systems for commercial use. The company onboarded a total of 68 participants and completed patient enrollment for key clinical studies. Operating expenses increased to $14.1 million, with a GAAP net loss of $14.3 million. Cash reserves totaled $42 million as of September 30, 2021. The company aims to expand the CellFX System's applications beyond dermatology.

Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 1:40 pm PT / 4:40 pm ET. The company, known for its innovative bioelectric medicine, aims to enhance patient care through its CellFX® System and Nano-Pulse Stimulation™ (NPS™) technology. The CellFX System treats dermatologic conditions effectively while preserving surrounding tissue. Interested parties can access the on-demand webcast via the Company’s website.

Pulse Biosciences, Inc. (NASDAQ: PLSE) will release its financial results for Q3 2021 on November 15, 2021, after market close. A conference call is scheduled at 1:30 PM PT for investors to discuss the results. The company is known for its innovative Nano-Pulse Stimulation™ (NPS™) technology, with its first commercial product, the CellFX® System, addressing dermatologic conditions. The system offers a multi-application platform with a utilization-based revenue model, aiming to enhance patient care and outcomes.

Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Laureen DeBuono to its Board of Directors, succeeding Kenneth Clark, who has resigned. DeBuono brings extensive executive experience in driving growth and shareholder value in life sciences and medical technology sectors. She has previously held positions at Rodan+Fields and served as CEO of govino, LLC. Her appointment aims to enhance the commercial growth of the CellFX® System in dermatology and expand the company’s multi-specialty bioelectric medicine profile.

Pulse Biosciences (NASDAQ: PLSE) announces its participation in the H.C. Wainwright Global Investment Conference on September 14, 2021. Management will hold one-on-one meetings and the event will feature a presentation webcast available starting on September 13, 2021, at 7:00 am ET. The company's CellFX® System, utilizing Nano-Pulse Stimulation™ technology, aims to improve dermatologic outcomes by treating various conditions while preserving adjacent non-cellular tissue. More information can be found on CellFX.com.

Pulse Biosciences (Nasdaq: PLSE) announces the appointment of Mitchell E. Levinson as the new Chief Strategy Officer, alongside his existing position on the board. Levinson, a veteran in the medical device industry with over 30 years of experience, aims to drive the company's expansion into multiple specialties, leveraging the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology. This strategic move is expected to enhance the company's dermatology business and facilitate broader applications of NPS technology, addressing unmet healthcare needs.

Pulse Biosciences (PLSE) reported its Q2 2021 financial results, highlighting significant developments in its CellFX System's launch and clinical trials. By the end of Q2, 49 clinics participated in the Controlled Launch Program, with 34 onboarded in that quarter. The company achieved Health Canada approval and initiated Canadian operations. Financially, cash reserves decreased to $47.4 million, with a net loss of $15.3 million. Non-GAAP operating expenses rose to $12.1 million, driven by increased commercialization efforts.